HAART simplification with lopinavir/ritonavir monotherapy in HIV/HCV co-infected patients starting anti-HCV treatment: a randomised pilot study (KaMon study)

被引：0
作者：
Hasson, Hamid [1 ]
Galli, Laura [1 ]
Gallotta, Giulia [1 ]
Neri, Valentina [2 ]
Blanc, Pierluigi [3 ]
D'annunzio, Marco [4 ]
Morsica, Giulia [1 ]
Sollima, Salvatore [5 ]
Merli, Marco [1 ]
Lazzarin, Adriano [1 ,6 ]
Uberti-Foppa, Caterina [1 ]
机构：
[1] IRCCS Osped San Raffaele, Dept Infect Dis, I-20127 Milan, Italy
[2] L Spallanzani Natl Inst Infect Dis, Rome, Italy
[3] SS Annunziata Hosp, Dept Infect Dis, Florence, Italy
[4] Univ Bari, Inst Infect Dis, I-70121 Bari, Italy
[5] L Sacco Hosp Vialba, Dept Infect & Trop Dis, Milan, Italy
[6] Univ Vita Salute San Raffaele, Milan, Italy
来源：
NEW MICROBIOLOGICA | 2012年 / 35卷 / 04期
关键词：
HAART-simplification strategy; Anti-HCV drugs; LPV/r monotherapy; Tolerability of HIV/HCV treatments; LOPINAVIR-RITONAVIR MONOTHERAPY; MAINTENANCE THERAPY; 2; NUCLEOSIDES; HIV; ANTIRETROVIRALS; SUPPRESSION; MANAGEMENT;
D O I：
暂无
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
The aim of this randomised, prospective, open-label, multicentre pilot clinical trial was to compare the 48-week toxicity profile of lopinavir/ritonavir (LPV/r) monotherapy with LPV/r-based HAART (KaMon = Kaletra monotherapy) in HIV/HCV patients undergoing HCV treatment. The study involved 30 HIV/HCV co-infected patients naive to anti-HCV therapy. One patient in each arm (6.7%) discontinued anti-HCV therapy because of adverse events. There were no significant between-group differences in terms of the proportion of patients experiencing AEs (p=0.999) or the number of grade 3-4 AEs (p=0.146). No HIV failure was observed. The safety profile of LPV/r monotherapy was similar to that of LPV/r-based HAART, thus encouraging HAART simplification in patients receiving anti-HCV treatment.
引用
收藏
页码：469 / 474
页数：6
相关论文
共 50 条
  • [31] The impact of HAART initiation timing on HIV-TB co-infected patients, a retrospective cohort study
    Yang, Chin-Hui
    Chen, Kuan-Jung
    Tsai, Jih-Jin
    Lin, Yu-Hui
    Cheng, Shu-Hsing
    Wang, Kwei-Feng
    Chiou, Hung-Yi
    BMC INFECTIOUS DISEASES, 2014, 14
  • [32] High levels of chronic immune activation in the T-cell compartment of HCV/HIV-1 co-infected patients on HAART is reverted by IFNα and ribavirin treatment
    Sandberg, Johan K.
    Falconer, Karolin
    Gonzalez, Veronica D.
    VIRULENCE, 2010, 1 (03) : 177 - 179
  • [33] Human pegivirus viremia in HCV/HIV co-infected patients: Direct acting antivirals exert anti-pegivirus effects
    Hlavay, B. A.
    Zhuo, R.
    Ogando, N.
    Charlton, C.
    Stapleton, J. T.
    Klein, M. B.
    Power, C.
    JOURNAL OF CLINICAL VIROLOGY, 2023, 162
  • [34] Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study
    Dominguez, Stephanie
    Ghosn, Jade
    Peytavin, Gilles
    Guiguet, Marguerite
    Tubiana, Roland
    Valantin, Marc Antoine
    Murphy, Robert
    Bricaire, Francois
    Benhamou, Yves
    Katlama, Christine
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (11) : 2445 - 2449
  • [35] Effect of HCV treatment with DAAs on serum intestinal fatty acid binding protein (I-FABP) as a marker of intestinal permeability in HCV/HIV co-infected patients
    Abdelhaleem, Hanan
    Khairy, Marwa
    Abdo, Mahmoud
    Cordie, Ahmed
    Elsharkawy, Marwa
    Alem, Shereen Abdel
    Elsharkawy, Aisha
    Al Sehemy, Lamiaa
    Esmat, Gamal
    EGYPTIAN LIVER JOURNAL, 2023, 13 (01)
  • [36] Treatment rate for HCV in the direct-acting antivirals era in HIV co-infected patients: data from an Italian cohort
    Cuomo, Gianluca
    Puzzolante, Cinzia
    Lazzaretti, Claudia
    Guaraldi, Giovanni
    Borghi, Vanni
    Mussini, Cristina
    MINERVA MEDICA, 2018, 109 (03) : 203 - 210
  • [37] Comparison of non-invasive liver fibrosis biomarkers in HIV/HCV co-infected patients:: The fibrovic study -: ANRS HC02
    Cacoub, Patrice
    Carrat, Fabrice
    Bedossa, Pierre
    Lambert, Jerome
    Penaranda, Guillaume
    Perronne, Christian
    Pol, Stanislas
    Halfon, Philippe
    JOURNAL OF HEPATOLOGY, 2008, 48 (05) : 765 - 773
  • [38] Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo Study
    Gianotti, Nicola
    Poli, Andrea
    Galli, Massimo
    Pan, Angelo
    Rizzardini, Giuliano
    Soria, Alessandro
    Viale, Pierluigi
    Di Biagio, Antonio
    Quirino, Tiziana
    Vigano, Paolo
    Bonfanti, Paolo
    Monforte, Antonella d'Arminio
    Fortino, Ida
    Lazzarin, Adriano
    NEW MICROBIOLOGICA, 2014, 37 (04) : 439 - 448
  • [39] Persistently Elevated Abnormal B-cell Subpopulations and Anti-Core Antibodies in Patients Co-Infected With HIV/HCV Who Relapse
    Kohli, Anita
    Funk, Emily
    Burbelo, Peter
    Barrett, Lisa
    Meissner, Eric G.
    Santich, Brian
    Shaffer, Ashton
    Johl, Jessica
    Sidharthan, Sreetha
    Moir, Susan
    Kottilil, Shyam
    Fauci, Anthony S.
    JOURNAL OF MEDICAL VIROLOGY, 2015, 87 (04) : 544 - 552
  • [40] HCV Viral Decline at Week 2 of Peg-IFN-Alpha-2a/RBV Therapy as a Predictive Tool for Tailoring Treatment in HIV/HCV Genotype 1 Co-Infected Patients
    Rivero-Juarez, Antonio
    Lopez-Cortes, Luis F.
    Camacho, Angela
    Torres-Cornejo, Almudena
    Gordon, Ana
    Ruiz-Valderas, Rosa
    Torre-Cisneros, Julian
    Pineda, Juan A.
    Viciana, Pompeyo
    Rivero, Antonio
    PLOS ONE, 2014, 9 (06):
12345